

January 2015

**ANNUAL DECLARATION OF INTERESTS  
GLOBAL INITIATIVE FOR ASTHMA: BOARD OF DIRECTORS  
1 January – 31 December 2014**

GINA Committee members disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

- 1. *Personal Benefits:*** Fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings.
- 2. *Shares:*** Refers to any shares in asthma related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/dependent children < 18 yrs). The company is to be listed, not the number of shares.
- 3. *Non-Personal Interests:*** Fees or grants paid to a GINA Committee member (or the Department/Institution on behalf of a GINA member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$1,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each member of the GINA Executive Committee for the year 2014 is presented in an effort to be as transparent as possible. For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Asthma (GINA)” on the website at: <<http://www.ginasthma.org>>.

**SUMMARY FOR YEAR 2014:**

**Eric Bateman, Cape Town, South Africa:** *Personal Benefits* \$10,000: Almirall, Cephalon, GlaxoSmithKline, Menarini, Pfizer, Peer Voice. *Personal Benefits* >\$10,000: AstraZeneca, Boehringer Ingelheim, ICON, Novartis, Takeda. *Shares:* none. *Non-Personal Interests:* none.

**Louis-Philippe Boulet, Quebec City, Quebec Canada:** *Personal Benefits* <\$10,000: AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Takeda. *Shares:* none. *Non-Personal Interests* >\$10,000: AllerGen NCE, Asmacure, AstraZeneca, Boehringer-Ingelheim, Genetech, GlaxoSmithKline, Novartis.

**Alvaro Cruz, Salvador, Brazil:** *Personal Benefits* <\$10,000: Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Roche. *Shares:* none. *Non-Personal Interests* >\$10,000: GlaxoSmithKline, Merck Sharp & Dohme.

**Mark FitzGerald, Vancouver, British Columbia, Canada:** *Personal Benefits* <\$10,000: Aerocrine, AstraZeneca, Boehringer-Ingelheim, Merck Sharp & Dohme, Novartis, Roche. *Personal Benefits* >\$10,000: none. *Shares:* none. *Non-Personal Interests* >\$10,000: AllerGen NCE, Boehringer Ingelheim, Canadian Institute for Health Research, Genetech, GlaxoSmithKline, Medimmune, Novartis, Wyeth.

**Tari Haahtela, Helsinki Finland:** *Personal Benefits <\$10,000:* Boehringer Ingelheim, Merck Sharp & Dohme, Orion. *Shares:* none. *Non-Personal Interests:* none.

**Mark Levy, London, England, UK:** *Personal Benefits <\$10,000:* AstraZeneca, Clement Clarke International, Novartis. *Personal Benefits ><\$10,000:* Chiesi (DSMB), Teva. *Shares:* none. *Non-Personal Interests <\$10,000:* none.

**Paul O'Byrne, Hamilton, Ontario, Canada:** *Personal Benefits <\$10,000:* AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Medimmune, Novartis, Verona. *Personal Benefits >\$10,000:* none. *Shares:* none. *Non-Personal Interests >\$10,000:* Ambit, Amgen, Novartis.

**Soren Pedersen, Kolding, Denmark:** *Personal Benefits <\$10,000:* Boehringer Ingelheim. *Personal Benefits >\$10,000:* GlaxoSmithKline. *Shares:* none. *Non-Personal Interests:* None.

**Helen K. Reddel, Camperdown Australia:** *Personal Benefits <\$10,000:* Boehringer-Ingelheim, Mundipharma, Merck Sharp & Dohme (DSMB), Teva. *Personal Benefits >\$10,000:* AstraZeneca (DSMB), GlaxoSmithKline (DSMB), Novartis (DSMB). *Shares:* none. *Non-Personal Interest >\$10,000:* AstraZeneca, GlaxoSmithKline.

**Stanley J. Szeffler, Denver Colorado US:** *Personal Benefits <\$10,000:* AstraZeneca, Boehringer-Ingelheim, Genentech, Merck Sharp & Dohme, Novartis, Roche. *Personal Benefits >\$10,000:* GlaxoSmithKline. *Shares:* none. *Non-Personal Interest >\$10,000:* GlaxoSmithKline.